
RegCell, a biotechnology company developing new treatments for autoimmune diseases, has raised a total of $66 million through a Series A financing and a non-dilutive grant from Japan’s Agency for Medical Research and Development (AMED).
The company raised $44 million in Series A funding led by Playground Global. New investors included Global Brain, Mitsui Chemicals, LG Technology Ventures, Alumni Ventures and Medical Incubator Japan. Existing investors including Fast Track Initiative, UTEC, Osaka University Venture Capital and Kyoto iCAP also participated.
RegCell also received approximately $22 million in non-dilutive funding from AMED.
The company is developing therapies designed to restore the immune system’s natural ability to control autoimmune disease. Its technology focuses on harmful immune cells and converts them into regulatory T cells (Tregs), which can help restore immune tolerance without broadly suppressing the immune system.
“We believe that patients need better options than what current autoimmune therapies provide,” said Michael V. McCullar, Ph.D., MBA, President and CEO of RegCell. “With this financing and AMED’s continued support, we intend to rapidly advance our epigenetic reprogramming platform into the clinic, establish proof of concept in patients, and expand its potential across autoimmune disease.”
“RegCell is pursuing something genuinely novel in autoimmune disease: instead of chasing a single target, the company’s approach reprograms a patient’s own auto-reactive T cells to reset the immune system on its own terms,” said Jory Bell, General Partner at Playground Global, and RegCell Board Member. “The company has the potential to move beyond symptom management toward something closer to a cure for conditions like myasthenia gravis, rheumatoid arthritis and ulcerative colitis.”
RegCell’s approach is based on research by Nobel Laureate and company co-founder Professor Shimon Sakaguchi, who discovered regulatory T cells.
The new AMED funding will support the development of RegCell’s next-generation platform, which aims to convert disease-causing T cells into stable, antigen-specific Tregs. The funding will also help expand the company’s clinical pipeline including an additional Phase 2 proof-of-concept study.
This is RegCell’s second AMED award. The agency has now committed approximately $59.3 million in non-dilutive funding to the company, including a $37.3 million award in 2024.
“Our conviction is that restoring immune tolerance through Treg biology could meaningfully change how autoimmune disease is treated. We look forward to building alongside Playground and RegCell’s team as it moves toward the clinic,” said Koji Yasuda, Principal at Fast Track Initiative and Board Director at RegCell.
“RegCell’s platform has the potential to redefine the treatment of autoimmune disease by restoring immune tolerance at its source rather than broadly suppressing the immune system,” said Azusa Shiohara, Principal at UTEC and Board Director at RegCell. “UTEC has supported RegCell since its early days in Japan and through the relocation of its headquarters to the U.S. Built on Prof. Sakaguchi’s Nobel Prize-winning science, RegCell and its world-class team are well positioned to bring this approach to patients worldwide.”
RegCell plans to use the combined funding to advance its immune tolerance platform into clinical-stage development across multiple autoimmune diseases.